Home > PPAR & PPAR & > Fenofibrate

Fenofibrate

菲诺贝特,非诺贝特

Fenofibrate是PPARα激动剂，对小鼠和人的PPARα的EC50分别为18 μM和30 μM。

目录号
EY0588
EY0588
纯度
99.56%
99.56%
规格
100 mg
200 mg
原价
190
370
售价
190
370
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Fenofibrate (Tricor, Trilipix) is a compound of the fibrate class and fibric acid derivative.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition: D. Panigrahy, et al.; PNAS 105, 985 (2008)
    [2] In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer: S.A. Saidi, et al.; Mol. Cancer 5, 13 (2006)
    [3] Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study: S. Pierno, et al.; Br. J. Pharmacol. 149, 909 (2006)

    分子式
    C20H21ClO4    		 分子量
    360.83    		 CAS号
    49562-28-9    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    60 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    35 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT02314533 Microalbuminuria Drug: fenofibrate Beijing Chao Yang Hospital Phase 4 2014-12-01 2014-12-09
    NCT01965834 Multiple Myeloma Drug: Fenofibrate University of Miami Phase 2 2012-03-01 2016-03-11
    NCT00246636 Hypertriglyceridemia Drug: Antara (fenofibrate) + Lovaza|Drug: Antara (fenofibrate) GlaxoSmithKline Phase 4 2005-10-01 2009-12-10
    NCT01023750 Hypertriglyceridemia|Insulin Resistance Drug: Fenofibrate University of Alabama at Birmingham|Tufts University|University of Minnesota - Clinical and Translational Science Institute Phase 4 2010-01-01 2015-10-11
    NCT01462877 Dyslipidemias|Cardiovascular Diseases|Hypertriglyceridemia Drug: fenofibrate Abbott|Rundo International Pharmaceutical Research & Development Co.,Ltd. Phase 4 2011-10-01 2015-02-25
    NCT01878227 Hyperlipoproteinemia Drug: Coenzyme A|Drug: Fenofibrate 200mg Zhejiang University Phase 3 2010-07-01 2013-06-11
    NCT00613613 Dyslipidemia Drug: fenofibrate|Drug: fenofibrate University of Minnesota - Clinical and Translational Science Institute|Laval University Phase 4 2008-01-01 2014-12-01
    NCT00552747 Coronary Heart Disease|Hyperlipidemia Drug: fenofibrate|Drug: placebo National Heart Institute, Mexico Phase 4 2007-10-01 2011-03-09
    NCT00928694 Dyslipidemia Drug: fenofibrate (U.S. formulation)|Drug: fenofibrate (UK formulation) Merck Sharp & Dohme Corp. Phase 1 2003-02-01 2015-08-18
    NCT01142323 Primary Sclerosing Cholangitis Drug: fenofibrate University of Miami|University of Florida Phase 1|Phase 2 2010-10-01 2013-03-12
    NCT01280604 Hyperlipidemias Drug: Fenofibrate 54mg Kaiser Permanente 2010-10-01 2015-06-04
    NCT00813527 Hyperlipidemias Drug: Lapaquistat acetate and fenofibrate|Drug: Fenofibrate Takeda Phase 2 2006-02-01 2012-05-23
    NCT02232360 Coronary Artery Disease Drug: Rosuvastatin and fenofibrate|Drug: Rosuvastatin alone Gachon University Gil Medical Center|Daewoong Pharmaceutical Co. LTD. Phase 3 2014-01-01 2016-08-22
    NCT02886299 Fenofibrate/Simvastatin Comparison Drug: Fenofibrate|Drug: Simvastatin Cairo University Phase 4 2013-10-01 2016-09-01
    NCT02965911 Primary Biliary Cirrhosis Drug: Fenofibrate|Drug: UDCA Beijing 302 Hospital Phase 1|Phase 2 2016-01-01 2016-11-15
    NCT00872599 Hypertension Drug: fenofibrate|Drug: Placebo Vanderbilt University|National Institutes of Health (NIH) Phase 4 2009-09-01 2013-06-19
    NCT00819910 Hypertriglyceridemia in Type 4 Hyperlipidemia|Non Diabetic Subjects With Normoglycemia Drug: Rosiglitazone|Drug: Placebo (Rosiglitazone)|Drug: Placebo (Fenofibrate)|Drug: Fenofibrate Ahmad Slim|GlaxoSmithKline|Brooke Army Medical Center Phase 4 2008-09-01 2014-04-08
    NCT00816829 Dyslipidemia|Sleep Apnea Syndrome|Overweight|Obesity Drug: Placebo|Drug: Fenofibrate Solvay Pharmaceuticals Phase 2 2005-09-01 2009-07-17
    NCT00575042 Primary Biliary Cirrhosis Drug: Fenofibrate (Insoluble Drug Delivery-Micro Particle Fenofibrate (IDD-P) University of Florida|The PBCers Organization|Shionogi Inc. Phase 2 2007-08-01 2011-12-02
    NCT00775359 Healthy Drug: Fenofibrate 160 mg tablets Ranbaxy Laboratories Limited|Ranbaxy Inc. 2002-08-01 2008-10-17
    NCT00775827 Healthy Drug: fenofibrate 160 mg tablets Ranbaxy Laboratories Limited|Ranbaxy Inc. 2002-11-01 2008-10-17
    NCT01109758 Healthy Drug: Fenofibrate Solvay Pharmaceuticals Phase 1 2008-03-01 2010-04-22
    NCT02823353 Primary Biliary Cirrhosis Drug: Fenofibrate|Drug: UDCA Xijing Hospital of Digestive Diseases Phase 3 2016-01-01 2016-07-05
    NCT01574131 Second or Third Degree Burns Drug: Fenofibrate|Drug: placebo The University of Texas Medical Branch, Galveston|Shriners Hospitals for Children Phase 4 2012-05-01 2016-02-09

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：